You are here

  • Home
  • Archive
  • Volume 79, Issue 7
  • Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD

Article info

Article menu
Download PDFPDF
Rheumatoid arthritis
Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD

Authors

  1. Correspondence to Nathan den Broeder, Rheumatology, Sint Maartenskliniek, 6574 NA Ubbergen, Netherlands; n.denbroeder{at}maartenskliniek.nl
View Full Text

Citation

Ulijn E, den Broeder N, Wientjes M, et al
Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
Annals of the Rheumatic Diseases 2020;79:867-873.

Publication history

  • Received January 14, 2020
  • Revised March 31, 2020
  • Accepted April 2, 2020
  • First published April 21, 2020.
Online issue publication 
April 10, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.